Novartis raises guidance and target price after strong execution

Novartis has recently raised its financial outlook and seen analysts lift price targets due to strong performance, especially in oncology drugs like Kisqali and Scemblix, and robust pipeline progress, signaling confidence in sustained growth despite some market caution. Key upgrades include higher mid-term sales growth targets (around 5-6% CAGR for 2025-2030) and boosted peak sales forecasts for specific drugs, supported by strong execution and strategic acquisitions.

https://www.marketscreener.com/news/novartis-raises-medium-term-growth-ambitions-as-target-price-is-lifted-ce7d51dcd18df722